TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Natural History Study in Subjects With Usher Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Must be willing to adhere to protocol for long-term follow-up as evidenced by written informed consent or parental permission and subject assent.~2. Subjects diagnosed with USH1.~3. Molecular diagnosis of USH1B due to MYO7A mutations (homozygotes or compound heterozygotes).~4. Age eight years old or older at the time of baseline.~5. Visual acuity ≥ 20/640 in at least one eye~Exclusion Criteria:~1. Unable or unwilling to meet requirements of the study.~2. Unable to communicate with suitable verbal/auditory and/or tactile sign language (in the opinion of the investigator)~3. Participation in a clinical study with an investigational drug in the past six months.~4. Pre-existing eye conditions that would interfere with the interpretation of study endpoints (for example, glaucoma, corneal or significant lenticular opacities, cystoid macular oedema, macular hole).~5. Complicating systemic diseases in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example, radiation treatment of the orbit; leukemia with CNS/optic nerve involvement). Also excluded would be subjects with immuno- compromising diseases, as there could be susceptibility to opportunistic infection \[such as cytomegalovirus (CMV) retinitis\].~6. Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g. macular edema or proliferative changes).~7. Prior ocular surgery within three months.~8. Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study and, in the opinion of the investigator, makes the potential subject unsuitable for the study.

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Chronic renal failure with an estimated glomerular filtration rate \< 60 milliliters per minute per 1.73 m\^2 and not expected to begin dialysis for at least 12 weeks.~2. Two consecutive hemoglobin values ≥ 8.0 g/dL and \< 11.0 g/dL within 4 weeks prior to randomization.~Exclusion Criteria:~1. Females who are pregnant or breast-feeding.~2. Treatment with an ESA in the 12 weeks prior to randomization.~3. Known intolerance to any ESA, parenteral iron supplementation, or pegylated molecule.~4. Prior chronic hemodialysis or chronic peritoneal dialysis treatment.~5. Known bleeding or coagulation disorder.~6. Known hematologic disease or cause of anemia other than renal disease.~7. Poorly controlled hypertension.~8. Evidence of active malignancy within one year prior to randomization~9. A scheduled kidney transplant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginesatide 0.025 mg/kg (Type: EXPERIMENTAL): None
- Peginesatide 0.04 mg/kg (Type: EXPERIMENTAL): None
- Darbepoetin alfa (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: the Effect of Dexmedetomidine in Coracoid Approach Brachial Plexus Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. American Society of Anesthesiologists (ASA) physical status I or II;~2. Aged 18-60 years;~3. The elbow, forearm, wrist or hand surgery~Exclusion Criteria:~1. History of allergy to local anesthetics;~2. Coagulation dysfunction, neuromuscular disease or local infection;~3. The operation time is longer than the local anesthetics effective time.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group Control (Type: EXPERIMENTAL): 40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
- Group Dexmedetomidine (Type: EXPERIMENTAL): 40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Application of Chlorhexidine to the Umbilical Cord for Prevention of Omphalitis and Neonatal Mortality in Rural District of Pakistan

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* All healthy newborns, born in the study setting will be systematically enrolled in the trial~Exclusion Criteria:~* Infants with congenital/birth defects~* Infants with any localized infection on the peri-umbilical region at the time of birth or application of any other material such as dung, etc before enrollment on the Cord.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 28 Days
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): In this arm we recruited 2,400 subjects who received Intervention.
- B (Type: EXPERIMENTAL): In this Arm, we recruited 2,400 subjects who received intervention.
- C (Type: EXPERIMENTAL): In this Arm, we recruited 2,400 subjects who received intervention.
- D (Type: NO_INTERVENTION): In this Arm, we recruited 2,400 subjects for Observation and comparison. This was the prime control group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exoskeletal-Assisted Walking in SCI Acute Inpatient Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Age 18 years or greater~* Height between 5'2 and 6'2 (1.6 meters to 1.9 meters)~* Weight less than 220 pounds (100 kilograms)~* Hip: 5 degrees of extension; 110 of flexion~* Knee: Full extension to 110 of flexion~* Ankle: at least 0 of dorsiflexion to 25 of plantarflexion~* Are eligible for locomotor training as part of inpatient rehabilitation~* Independent with static sitting balance~* Sufficient function upper extremity strength to manage walking aid (front-wheeled walker, platform walker, or crutches)~* Able to follow directions~Exclusion Criteria~* Uncontrolled cardiovascular conditions (i.e. heart failure, angina, hypertension)~* Inability to stand upright due to orthostatic hypotension~* Any form of progressive SCI as defined by the physician, such as cancers~* Body characteristics that do not fit within exoskeleton limits~* Upper leg length discrepancy \> 0.5 or lower leg discrepancy \>0.75~* Skin integrity issues in areas that would contact the device or that would likely be made worse by device use~* Pregnancy~* Colostomy~* Mechanical ventilation~* Non-English Speaking~* The participant is able to walk better with exoskeleton assistance at baseline~* Any other issue that might prevent safe standing or walking

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exoskeletal-assisted walking training group (Type: EXPERIMENTAL): Participants will receive locomotor training provided with an Ekso™ powered exoskeleton according to the standard of care of AIR at Mount Sinai Hospital with the exception that the EAW training will be incorporated into the designated therapy times (3 hours of physical therapy (PT) and/or occupational therapy (OT)) which will be provided as determined by the clinical team from the earliest time they are identified to be able to safely stand, through discharge. The goal of EAW intervention is to complete three or more sessions of EAW training a week during the AIR period (after enrolling into the study until discharge).
- Standard of care group (Type: ACTIVE_COMPARATOR): Participants will receive standard of care of acute inpatient rehabilitation which includes three hours of physical therapy and/or occupational therapy per day until they are discharged.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV Infection documented CD4+ count within the last 30 days (or drawn with screening labs)~* Currently on a stable 3-drug HAART regimen including 2 NRTIs for \> 6 month viral load (VL) \< 50/mm3 for \> 6 months, last within the last 30 days (or drawn with screening labs)~* Partial immune responder or immune non-responder~* Age \> 18 years~* Labs (drawn at screening)~* Alanine transaminase (ALT) \< 5 X the upper limit of normal (ULN)~* Total bili \< 2 X ULN~* Creatinine \< 2.0 mg/dL~Exclusion Criteria:~* Prior therapy with Kaletra~* Known hypersensitivity to Ritonavir~* Therapy the drugs with potential serious drug interactions: flecainide, propafenone, astemizole, terfenadine, rifampin, dihydroergotamine, ergonovine, ergotamine, methylergonovine, cisapride, pimozide, lovastatin, simvastatin, midazolam, triazolam, and St. John's wart.~* Pregnancy; breast feeding~* Current malignancy requiring CT~* Use of systemic corticosteroids, immunosuppressive, or cytotoxic agents within the last 45 days~* Fever and/or evidence of an active infectious complication~* Currently in another interventional clinical trial~* Receiving Interleukin-2 (IL-2) or any other cytokine or growth factor~* Enrollment in another interventional clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Kaletra + Current Dual NRTI Backbone (Type: EXPERIMENTAL): Patients in this arm received Kaletra in addition to their current Dual NRTI Backbone.
- Current Regimen (Type: ACTIVE_COMPARATOR): Patients in this study arm continued their current regimen.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of BN101 in Subjects With Chronic Graft Versus Host Disease (cGVHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects at least 18 years of age who have had allogenic hematopoietic cell transplant (HCT).~* Previously received at least 1 and not more than 5 lines of systemic therapy for cGVHD~* Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to screening;~* Have persistent cGVHD manifestations and systemic therapy is indicated~Exclusion Criteria:~* Subject has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic investigational GVHD treatments are not permitted).~* Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.~* Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a washout of at least 28 days prior to treatment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 200mg qd (Type: EXPERIMENTAL): 200mg qd po.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assess Aesthetic Improvement and Onset of QM1114-DP in Subjects With Moderate to Severe Glabellar Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female 18 years or older~* Moderate to severe GL at maximum frown as assessed by the Investigator~* Moderate to severe GL at maximum frown as assessed by the subject~Exclusion Criteria:~* Previous use of any botulinum toxin in facial areas within 9 months prior to study treatment~* Female who is pregnant, breast feeding or intends to conceive a child during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Active arm - QM1114-DP (Type: ACTIVE_COMPARATOR): a Botulinum Toxin Type A (BoNT-A)
- Inactive arm - Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial on Clinical Efficacy of 1% Versus 2% Lignocaine in Cough Suppression and Pain Relief in Patients Undergoing Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients undergoing flexible bronchoscopy~* Hemodynamic stability~Exclusion Criteria:~* Patients receiving sedatives during the course of their treatment~* Patients undergoing conventional TBNA and/or EBUS-TBNA who are likely to receive sedation~* Patients with known hypersensitivity to lignocaine~* Not willing to provide informed consent

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 1% lignocaine (Type: EXPERIMENTAL): Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.
- 2% lignocaine (Type: ACTIVE_COMPARATOR): Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as spray as you go technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age equal to or above 18 years~* Male or female gender~* In case of women, unwillingness to remain pregnant during the study period~* Written informed consent provided by the patient or by one first-degree relative/spouse in case of patients unable to consent~* Community-acquired pneumonia or hospital-acquired pneumonia or ventilator-associated pneumonia or primary bacteremia or acute cholangitis~* Sepsis defined by the Sepsis-3 definitions.~* Patients with laboratory diagnosis of MALS or hypo-inflammation (immune-paralysis) based on two consecutive blood sampling with 24 hours apart. MALS is defined as the presence of ferritin \>4,420 ng/ml and hypo-inflammation as HLA-DR expression on CD14-monocytes (co-expression) less than 30%~Exclusion Criteria:~* Age below 18 years~* Denial for written informed consent~* Acute pyelonephritis or intraabdominal infection other than AC, meningitis or skin infection. It is explicitly stated that in the case of a patient with both AC and any other type of intraabdominal infection, the patient cannot be enrolled.~* Any stage IV malignancy~* Any do not resuscitate decision~* In the case of BSI, patients with blood cultures growing coagulase-negative staphylococci or skin commensals or catheter-related infections cannot be enrolled.~* Active tuberculosis (TB) as defined by the co-administration of drugs for the treatment of TB~* Infection by the human immunodeficiency virus (HIV)~* Any primary immunodeficiency~* Oral or IV intake of corticosteroids at a daily dose equal or greater than 0.4 mg prednisone or greater the last 15 days~* Any anti-cytokine biological treatment the last one month~* Medical history of systemic lupus erythematosus~* Medical history of multiple sclerosis or any other demyelinating disorder~* Pregnancy or lactation. Women of child-bearing potential will be screened by a urine pregnancy test before inclusion in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Anakinra (Type: EXPERIMENTAL): Treatment with iv anakinra 200 mg three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
- IV Placebo (Type: PLACEBO_COMPARATOR): Treatment with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days and sc 1ml N/S 0.9% every other day for 15 days
- Recombinant human interferon-gamma (Type: EXPERIMENTAL): Treatment with sc recombinant human interferon-gamma every other day for a total of 15 days and with iv 1ml N/S 0.9% three times daily (every eight hours) for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Depth of Neuromuscular Block on Surgical Operating Conditions in Gynecologic Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who give written informed consent to the study~* Age: 18-60 years~* ASA risk class: I - II~* Elective gynecologic laparoscopic surgery lasting \<60 min (excision of ovarian cyst, endometriosis)~Exclusion Criteria:~* Lack of consent~* Body Mass Index (BMI)\> 30 Kg/m2~* Patients with renal and hepatic dysfunction~* Neuromuscular disorders~* Known hypersensitivity to study drugs~* Pregnant patients~* Conversion to laparotomy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Group DNMB (Type: EXPERIMENTAL): Deep Neuromuscular Block group Intervention: maintenance of a deep neuromuscular block by infusion of rocuronium at the starting dose of 0.3-0.6 mg / kg / h, titrated to maintain a TOF count of 0, and a PTC between 1-2.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)
- Group MNMB (Type: ACTIVE_COMPARATOR): Moderate Neuromuscular Block group Intervention: maintenance of a moderate neuromuscular block. neuromuscular blockade will be maintained with intravenous bolus of rocuronium (0.15-0.25 mg/kg) titrated to obtain a TOF count of 1-3.~Quality of surgical field conditions' assessed by a blind surgeon as a 5 points scale (Optimal= 5 points/ Good= 4 points / Adequate= 3 points / Poor = 2 points / Inadequate = 1 point)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phototoxic Doses of Ultraviolet A for Treatment of Alopecia Areata

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients presenting with alopecia areata, patchy type (max 3 patches not exceeding 50% of the scalp surface area) of more than 2 months duration.~* Age: 12 years and above~Exclusion Criteria:~* Age: Less than 12 years old.~* Affection of more than 50% of the scalp area~* Diagnosis or history of local dermatological disease in the scalp apart from AA such as eczema, seborrheic dermatitis, psoriasis,..~* Any present / past history of dermatological disease with a potential for koebnerization such as psoriasis, vitiligo.~* Diagnosis or history of any contraindication to receiving phototherapy such as malignancy, systemic lupus~* Dermoscopic evaluation revealing absence of any signs of presence of hair follicles.~* Any psychiatric illness or psychological state impairing future compliance or influencing expectations of the patient.~* Patients with AA totalis or Ophiasis

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Phototherapeutic (Type: EXPERIMENTAL): 0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).~UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions.
- Conventional therapy (Type: ACTIVE_COMPARATOR): One monthly injections of intralesional potent corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete